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Introduction {#sec005}
============

Human herpesviruses (HHVs) are DNA viruses, and eight distinct members of the HHV family have been identified.\[[@pone.0184699.ref001]\] Most HHVs remain latent for a long time but can be reactivated and cause infection when host immunity is compromised.\[[@pone.0184699.ref002]\] Some studies have reported that reactivation of HHVs occurs in the colonic mucosa.\[[@pone.0184699.ref003]\]

The etiopathogenesis of inflammatory bowel disease (IBD) remain elusive, and accumulating evidence indicates that both mucosal immune dysregulation and genetics are involved in the disease process.\[[@pone.0184699.ref004]\] Individuals with IBD are often placed on long-term immunosuppressant drugs and may develop iatrogenic immunosuppression with consequent reactivation of HHVs in colonic mucosa. Cytomegalovirus (CMV) is frequently detected in the colonic mucosa of IBD individuals,\[[@pone.0184699.ref005]\] but detection of HHVs other than CMV in their colonic mucosa has not been reported.

A previous study showed that the detection rates of Epstein--Barr virus (EBV) and CMV were higher in IBD individuals than in immunocompetent (IC) individuals.\[[@pone.0184699.ref006]\] Another study showed that the detection rates of herpes simplex virus (HSV)-1 and HHV-6 were higher in stool samples of HIV-infected individuals than in those of IC individuals.\[[@pone.0184699.ref007]\] However, no previous studies have compared the detection rate of eight HHVs---HSV-1/2, varicella zoster virus (VZV), CMV, EBV, HHV-6, HHV-7, and HHV-8---among these three groups. For the identification and diagnosis of CMV in colonic mucosa, the European Crohn's & Colitis Organization (ECCO) guidelines recommend mucosal PCR assay as a highly specific and sensitive method for verifying CMV infection in biopsy tissue.\[[@pone.0184699.ref008]\] Accordingly, we evaluated colonic mucosa by performing mucosal PCR assay for the eight HHVs.

This study aimed to determine the detection rates of the eight HHVs in individuals with IBD and examine the correlation between HHV infection rate and host immune status in IC, IBD, and HIV-infected individuals, as well as identify the difference in HHV infection rates between ulcerative colitis (UC) and Crohn's disease (CD).

Materials and methods {#sec006}
=====================

Study design, setting, and participants {#sec007}
---------------------------------------

This retrospective observational study was conducted between 2011 and 2015 at the endoscopy unit of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. During the study period, we reviewed the data of 121 biopsy samples from 121 individuals who had colorectal ulcer confirmed on colonoscopy. The indications for colonoscopy were examination for lower gastrointestinal symptoms such as diarrhea, hematochezia, or abdominal symptoms. In clinical practice, we obtained pure biopsy samples from UC mucosa to differentiate between pathogenic bacteria-induced and virus-induced colorectal ulcer. To diagnose virus-induced ulcer in particular, we sought to definitively clarify the HHV detection rate in active inflammatory mucosa of the ulcer. All colorectal ulcers were diagnosed by high-resolution colonoscopy (Olympus AI260 Series, Olympus, Japan) with biopsy forceps (Boston Scientific single-use Radial JAW^TM^4 (2.8 mm) Boston, MA). We divided the study participants into IC, IBD, and HIV groups, respectively. The IC group comprised individuals with colonic ulcers due to non-virus infectious colitis, ischemic colitis, or nonspecific colitis, excluding those with HIV, IBD, renal insufficiency/dialysis, diabetes mellitus, liver cirrhosis, or cancer and those receiving prednisolone (PSL) or immunosuppressive therapy. The IBD group comprised individuals with a diagnosis of IBD based on clinical, endoscopic, radiologic, and histologic parameters.\[[@pone.0184699.ref009]\] Before endoscopy, all individuals are tested for HIV infection in our institution, and the HIV group comprised those study participants with a positive HIV test. Ultimately, a total of 89 individuals---26 in the IC group, 41 in the IBD group, and 22 in the HIV group, were selected for analysis.

The institutional review board at NCGM approved this study (approval number 2045). Written informed consent was obtained from all participants.

Clinical factors and endoscopic findings {#sec008}
----------------------------------------

Clinical factors and endoscopic findings were reviewed from an electronic medical database (MegaOak, NEC, Tokyo, Japan). For the IBD group, we collected data on disease duration, extent of disease, disease activity, and medication on the day of colonoscopy. Disease activity was assessed by the Disease Activity Index (DAI)\[[@pone.0184699.ref010]\] in UC, and the International Organization for the study of Inflammatory Bowel Disease (IOIBD) endoscopic index\[[@pone.0184699.ref011]\] in CD. DAI score was divided into four categories of severity (0--2, 3--5, 6--10, and 10--12) as previously reported.\[[@pone.0184699.ref010]\] Treatment administered included 5-aminosalicylic, PSL, azathioprine, apheresis, tacrolimus, cyclosporine, infliximab, and adalimumab. PSL dose was the total amount received within 4 weeks prior to the day of endoscopy.\[[@pone.0184699.ref012]\]

DNA extraction and PCR assay {#sec009}
----------------------------

DNA for PCR was extracted from ulcerative colonic mucosa obtained from participants at colonoscopy using a QIAamp DNA Mini Kit (Qiagen, Tokyo, Japan) according to the manufacturer's instructions.

In some cases, the amount of extracted DNA was insufficient for quantitative real-time PCR for the eight HHVs. To evaluate the pathogenesis of gastrointestinal disease, we considered EBV, CMV, and HHV-8 more important than the other viruses, so we measured them by quantitative real-time PCR. We used the multiplex PCR method to detect HSV-1/2, HHV-6A/6B, and HHV-7 and conventional PCR to detect VZV \[[@pone.0184699.ref013]\]. Quantitative real-time PCR was performed using 50 ng DNA each and TaqMan Universal PCR Master Mix (Thermo Fisher Scientific, Kanagawa, Japan), with previously published sets of primers and probes for EBV and CMV,\[[@pone.0184699.ref014],[@pone.0184699.ref015]\] and the 7900HT Fast Real Time PCR System (Thermo Fisher Scientific). Primers and probes for HHV-8 detection were: forward primer (`5’- GAT TCC ACC ATT GTG CTC GAA T -3’`, position: 47296--47317 of HHV-8 \[U75698\]), reverse primer (`5’- TAC ACC AAC AGC TGC TGC AGA A -3’`, position: 47396--47375), and probe (`5’ [FAM]- ACG GAT TTG ACC TCG TGT TCC CCA TG -[TAMRA] 3’`, position: 47321--47346). Thermal cycles were 50°C for 2 min and 95°C for 10 min, then 50 cycles of 95°C for 15 s, and 60°C for 60 s. Multiplex PCR was performed to amplify viral DNA of HSV-1/2, HHV-6A/6B, and HHV-7 using 50 ng of extracted DNA by the method reported by Tanaka et al.\[[@pone.0184699.ref013]\] with slight modification. Briefly, the KAPA2G Fast Multiplex PCR Kit (Kapa Biosystems, Inc., Wilmington, MA) was used with the following thermal cycles: 95°C for 3 min, then touchdown cycles of 95°C for 15 s, 70 to 61°C for 30 s (1°C decrease in temperature per cycle), and 72°C for 20 s, and finally 30 cycles of 95°C for 15 s, then 60°C for 30 s and 72°C for 20 s. Conventional PCR was performed separately for the detection of VZV-DNA using a published primer set\[[@pone.0184699.ref013]\] and 50 ng DNA with the following thermal cycles: 95°C for 10 min, then touchdown cycles of 95°C for 30 s, 70 to 61°C for 30 s (1°C decrease in temperature per cycle), and 72°C for 1 min, and finally 35 cycles of 95°C for 30 s, then 60°C for 30 s, and 72°C for 30 s. PCR products were evaluated by 3% NuSieve 3:1 Agarose electrophoresis (Lonza Japan, Tokyo, Japan). Detection limit of the copy number of each virus was 80 copies/μg DNA. Positive controls used for each viral DNA were purchased from Advanced Biotechnologies Inc. (Eldersburg, MD).

Statistical analysis {#sec010}
--------------------

We compared nominal variables or continuous variables between groups using the χ^2^, Fisher's exact, Mann--Whitney *U*, or Kruskal--Wallis tests as appropriate. The χ^2^ test for trend was used to examine the HHV positivity rate in the order of the IC, IBD, and HIV groups. There were no IBD individuals with HSV-1, HSV-2, VZV, or HHV-8. Therefore, we performed multiple logistic regression analysis adjusting for age and sex among the three groups with EBV, CMV, HHV-6, or HHV-7. We also compared the HHV positivity rate between IBD individuals receiving immunosuppressive therapy and those not receiving it and between untreated HIV-infected individuals with low CD4 and treated HIV-infected individuals. Statistical significance was set at P \< 0.05. All statistical analyses were performed using Stata software (version 14, Stata Co., College Station, TX).

Results {#sec011}
=======

Baseline characteristics of IC, IBD, and HIV-infected individuals {#sec012}
-----------------------------------------------------------------

[**Table** 1](#pone.0184699.t001){ref-type="table"}. shows the characteristics of the three groups.

10.1371/journal.pone.0184699.t001

###### Characteristics of the IC, IBD, and HIV-infected groups (N = 89).

![](pone.0184699.t001){#pone.0184699.t001g}

  Factors                                                           IC group (n = 26)   IBD group (n = 41)   HIV-infected group (n = 22)
  ----------------------------------------------------------------- ------------------- -------------------- ----------------------------------------------------------------
  Age (range) years                                                 50 (21--81)         42 (16--91)          40.5 (28--80)
  Sex, male                                                         15 (57.7%)          24 (58.5%)           22 (100%)
  PSL                                                               0                   12 (29.3%)           1 (4.5%)
  [^a^](#t001fn002){ref-type="table-fn"}Immunosuppressive therapy   0                   7 (17.1%)            0
  CD4 cell counts (cells/μL)                                                                                 119.5 (4--1287)
  AIDs status                                                                                                14 (63.6%)
  HIV VL (copies/mL)                                                                                         [^b^](#t001fn003){ref-type="table-fn"}300,000 (110--5,000,000)
  VL ≤ 50 (normal range)                                                                                     6 (27.3%)
  VL \> 50                                                                                                   16 (72.7%)
  Administration of HAART                                                                                    10 (45.5%)
  No HAART and CD4 \< 100 (cells/μL)                                                                         8 (36.4%)

Note

^a^Immunosuppressive therapy is defined as prednisolone, azathioprine, or TNF-α inhibitor.

^b^300,000 (110--5,000,000) is the median (range) HIV viral load in 16 (72.7%) individuals with HIV VL \> 50.

**Abbreviations**: IC, immunocompetent; IBD, inflammatory bowel disease; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; PSL, prednisolone; VL, viral load.

No significant difference in age was observed among the three groups (P = 0.17). No significant sex difference was observed between the IC and IBD groups (P = 0.20), and the HIV group comprised men only. None of the IC group had received PSL or immunosuppressive therapy. Twelve individuals in the IBD group (29.3%) received PSL and 7 (17.1%) received immunosuppressive therapy. One patient in the HIV group (4.5%) received PSL. In the HIV group, median CD4 cell count was 119.5/μl (range, 4-1287/μl) and 11 (50%) individuals had CD4 cell count \< 100/μl. **[Table 2](#pone.0184699.t002){ref-type="table"}** shows the characteristics of UC and CD individuals.

10.1371/journal.pone.0184699.t002

###### Characteristics of the IBD group (n = 41).

![](pone.0184699.t002){#pone.0184699.t002g}

                                           UC (n = 33)             CD (n = 8)      P
  ---------------------------------------- ----------------------- --------------- -------
  Disease duration                                                                 
      \< 1 year                            15 (45.5%)              4 (50.0%)       0.38
      1--5 years                           7 (21.2%)               0               
      \> 5 years                           10 (30.3%)              3 (37.5%)       
      Unknown                              1 (3.0%)                1 (12.5%)       
  Extent of disease                        Pancolitis 20 (60.6%)   Ileum 0         NA
  Left 13 (39.4%)                          Colon 4 (50%)                           
                                           Ileocolon 4 (50%)                       
  Disease activity                                                                 
  DAI score in UC, mean ± SD               7.8 ± 3.1                               
      0--2                                 4 (12.1%)                               
      3--5                                 3 (9.1%)                                
      6--10                                20 (60.6%)                              
      11--12                               6 (18.2%)                               
  IOIBD score in CD, mean ± SD                                     2.5 ± 1.3       
      1                                                            2 (25.0%)       
      2                                                            3 (37.5%)       
      3                                                            0               
      4                                                            3 (37.5%)       
      ≥ 5                                                          0               
  Medication                                                                       
    5-aminosalicylic acid                  26 (78.8%)              5 (62.5%)       0.38
    PSL                                    10 (30.3%)              2 (25.0%)       1.0
    All PSL (mg) during 4W, median (IQR)   242.5 (140,880)         280 (240,320)   0.81
    Azathioprine                           5 (15.2%)               1(12.5%)        1.0
    Apheresis                              1 (3%)                  0               1.0
    Tacrolimus                             0                       0               NA
    Cyclosporin                            0                       0               NA
    Infliximab                             1 (3%)                  2 (25%)         0.092
    Adalimumab                             0                       0               NA

**Abbreviations**: IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; DAI, Disease Activity Index; IOIBD, International Organization for the Study of Inflammatory Bowel Disease; IQR, interquartile range; PSL, prednisolone; SD, standard deviation; NA, not applicable.

No significant difference in disease duration or medication was found between UC and CD individuals. Twenty UC individuals (60.6%) had pancolitis and 4 CD individuals (50%) had ileocolic lesions. Mean DAI score was 7.8 in UC and 2.5 in CD.

Mucosal HHV PCR positivity rate in IC, IBD, and HIV-infected individuals {#sec013}
------------------------------------------------------------------------

**[Fig 1](#pone.0184699.g001){ref-type="fig"}** shows the positivity rate of the eight HHVs in colonic mucosa and a comparison between the three groups for HSV-1 (**[Fig 1A](#pone.0184699.g001){ref-type="fig"}**), HSV-2 (**[Fig 1B](#pone.0184699.g001){ref-type="fig"}**), VZV (**[Fig 1C](#pone.0184699.g001){ref-type="fig"}**), EBV **([Fig 1D](#pone.0184699.g001){ref-type="fig"}**), CMV (**[Fig 1E](#pone.0184699.g001){ref-type="fig"}**), HHV-6 (**[Fig 1F](#pone.0184699.g001){ref-type="fig"}**), HHV-7 (**[Fig 1G](#pone.0184699.g001){ref-type="fig"}**), and HHV-8 (**[Fig 1H](#pone.0184699.g001){ref-type="fig"}**).

![Mucosal HHV PCR positivity rate in the IC, IBD, and HIV-infected groups.\
Note: Bars represent standard error. Abbreviations: CMV, cytomegalovirus; EBV, Epstein--Barr virus; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV-1/2, herpes simplex virus-1/2; IBD, inflammatory bowel disease; IC, immunocompetent; NA, not applicable; VZV, varicella zoster virus.](pone.0184699.g001){#pone.0184699.g001}

The HSV-1 positivity rate was 1.1% in all individuals and showed no significant difference between the three groups (3.8%, 0%, and 0% in the IC, IBD, and HIV groups, respectively). The HSV-2 positivity rate was 1.1% in all individuals and also showed no significant difference between the three groups (3.8%, 0%, and 0% in the IC, IBD, and HIV groups, respectively). Likewise, the VZV positivity rate was 2.2% in all individuals and showed no significant difference between the three groups (7.7%, 0%, and 0% in the IC, IBD, and HIV groups, respectively).

The EBV positivity rate was 49.4% in all individuals and showed a significantly increasing trend in the order of 23.1%, 53.7%, and 72.7% in the IC, IBD, and HIV groups, respectively (**[Fig 1D](#pone.0184699.g001){ref-type="fig"}**; P for trend = 0.0005). Multivariate analysis revealed a significantly increasing trend of EBV infection risk in the IBD group and HIV group compared with the IC group ([Table 3](#pone.0184699.t003){ref-type="table"}; P for trend = 0.008).

10.1371/journal.pone.0184699.t003

###### Crude and adjusted odds ratios of the infection risk of four HHVs in the IBD group and HIV group compared with the IC group.

![](pone.0184699.t003){#pone.0184699.t003g}

  Outcomes        Crude odds ratio (95% CI)   P           P for trend   Adjusted odds ratio (95% CI)   P           P for trend
  --------------- --------------------------- ----------- ------------- ------------------------------ ----------- -------------
  EBV                                                                                                              
      IC group    1 (referent)                                          1 (referent)                               
      IBD group   3.9 (1.3--11.6)             **0.016**                 4.2 (1.3--13.2)                **0.014**   
      HIV group   8.9 (2.4--33.0)             **0.001**   **0.004**     9.5 (2.2--40.9)                **0.003**   **0.008**
  CMV                                                                                                              
      IC group    1 (referent)                                          1 (referent)                               
      IBD group   3.9 (0.8--19.3)             0.099                     5.2 (0.9--29.3)                0.059       
      HIV group   14.4 (1.7--76.4)            **0.002**   **0.004**     20.8 (3.0--141.9)              **0.002**   **0.007**
  HHV-6                                                                                                            
      IC group    1 (referent)                                          1 (referent)                               
      IBD group   0.75 (0.28--2.0)            0.57                      0.71 (0.25--2.0)               0.53        
      HIV group   0.34 (0.097--1.2)           0.096       0.24          0.41 (0.97--1.7)               0.22        0.47
  HHV-7                                                                                                            
      IC group    1 (referent)                                          1 (referent)                               
      IBD group   1.4 (0.51--4.1)             0.49                      1.2 (0.40--3.7)                0.73        
      HIV group   0.66 (0.18--1.0)            0.53        0.42          0.57 (0.13--2.5)               0.46        0.51

**Note**: Bold indicates P \< 0.05.

**Abbreviations**: CI, confidence interval; CMV, cytomegalovirus; EBV, Epstein--Barr virus; HHV, human herpesviruses; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IC, immunocompetent.

The CMV positivity rate was 27.0% in all individuals and showed a significantly increasing trend in the order of 7.7%, 24.4%, and 54.5% in the IC, IBD, and HIV groups, respectively (**[Fig 1E](#pone.0184699.g001){ref-type="fig"}**; P for trend = 0.0003). Multivariate logistic analysis revealed a significantly increasing trend of CMV infection risk in the IBD group and HIV group compared with the IC group (**[Table 3](#pone.0184699.t003){ref-type="table"}**; P for trend = 0.007).

The HHV-6 positivity rate was 37.1% in all individuals and showed a marginally significant decreasing tendency in the order of 46.2%, 39.0%, and 22.7% in the IC, IBD, and HIV groups, respectively (**[Fig 1F](#pone.0184699.g001){ref-type="fig"}**; P for trend = 0.099). Multivariate analysis revealed no significantly increasing trend of HHV-6 infection risk in the IBD group or HIV group compared with the IC group (**[Table 3](#pone.0184699.t003){ref-type="table"}**; P for trend = 0.47).

The HHV-7 positivity rate was 32.6% in all individuals and 30.8%, 39.0%, and 22.7% in the IC, IBD, and HIV groups, respectively. Multivariate analysis revealed no significantly increasing trend of HHV-7 infection risk in the IBD group or HIV group compared with the IC group (**[Table 3](#pone.0184699.t003){ref-type="table"}**; P for trend = 0.51).

The HHV-8 positivity rate was 2.2% in all individuals and 0%, 0%, and 3.8% in the IC, IBD, and HIV groups, respectively.

Quantitative mucosal EBV PCR and CMV PCR in IC, IBD, and HIV-infected individuals {#sec014}
---------------------------------------------------------------------------------

**[Fig 2](#pone.0184699.g002){ref-type="fig"}** shows the values of mucosal HHV PCR in colonic mucosa and the comparison between the three groups for EBV ([Fig 2A](#pone.0184699.g002){ref-type="fig"}) and CMV ([Fig 2B](#pone.0184699.g002){ref-type="fig"}). Both values showed a significantly increasing trend in the order of the IC, IBD, and HIV-infected groups.

![Quantitative mucosal EBV and CMV in the IC, IBD, and HIV-infected groups.\
**Note**: ^a^95,286 copies/μg DNA, ^b^172,000 and 498,000 copies/μg DNA. **Abbreviations**: CMV, cytomegalovirus; EBV, Epstein--Barr virus; HHV, human herpesvirus; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IC, immunocompetent.](pone.0184699.g002){#pone.0184699.g002}

Median mucosal EBV DNA values in the IC, IBD, and HIV groups were 0, 76, and 287 copies/μg DNA, respectively, showing a significant difference between the IC and IBD groups (P = 0.013) and between the IC and HIV groups (P = 0.002). Median mucosal CMV DNA values in the IC, IBD, and HIV groups were 0, 0, and 17 copies/μg DNA, respectively, for a significant difference between the IC and HIV groups (P = 0.0003) and between the IBD and HIV groups (P = 0.013). A significantly increasing trend was seen in the order of the IC, IBD, and HIV groups for values of mucosal EBV (P for trend = 0.002) and values of mucosal CMV (P for trend = 0.0001).

Mucosal HHV PCR positivity rate in UC and CD individuals {#sec015}
--------------------------------------------------------

**[Fig 3](#pone.0184699.g003){ref-type="fig"}** shows the positivity rate of the eight HHVs in colonic mucosa and a comparison between UC and CD individuals for HSV-1 (**[Fig 3A](#pone.0184699.g003){ref-type="fig"}**), HSV-2 (**[Fig 3B](#pone.0184699.g003){ref-type="fig"}**), VZV (**[Fig 3C](#pone.0184699.g003){ref-type="fig"}**), EBV (**[Fig 3D](#pone.0184699.g003){ref-type="fig"}**), CMV (**[Fig 3E](#pone.0184699.g003){ref-type="fig"}**), HHV-6 (**[Fig 3F](#pone.0184699.g003){ref-type="fig"}**), HHV-7 (**[Fig 3G](#pone.0184699.g003){ref-type="fig"}**), and HHV-8 (**[Fig 3H](#pone.0184699.g003){ref-type="fig"}**). No significant differences in the positivity rates of the eight HHVs were observed between the two groups.

![Mucosal HHV PCR positivity rate in UC and CD individuals (n = 41).\
**Note**: Bars represent standard error. **Abbreviations**: CMV, cytomegalovirus; EBV, Epstein--Barr virus; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV-1/2, herpes simplex virus-1/2; IBD, inflammatory bowel disease; IC, immunocompetent; NA, not applicable; VZV, varicella zoster virus.](pone.0184699.g003){#pone.0184699.g003}

Mucosal HHV PCR positivity rate in IBD individuals with and without IS therapy {#sec016}
------------------------------------------------------------------------------

Of the 41 IBD individuals, 17 (41.5%) were included in the IS therapy group, defined as individuals taking PSL, AZA, or TNF-α inhibitors. **[S1 Fig](#pone.0184699.s001){ref-type="supplementary-material"}** shows the positivity rate of the eight HHVs in colonic mucosa and a comparison between the IS therapy group and the non-IS therapy group for HSV-1 (**[S1A Fig](#pone.0184699.s001){ref-type="supplementary-material"}**), HSV-2 (**[S1B Fig](#pone.0184699.s001){ref-type="supplementary-material"}**), VZV (**[S1C Fig](#pone.0184699.s001){ref-type="supplementary-material"}**), EBV (**[S1D Fig](#pone.0184699.s001){ref-type="supplementary-material"}**), CMV (**[S1E Fig](#pone.0184699.s001){ref-type="supplementary-material"}**), HHV-6 (**[S1F Fig](#pone.0184699.s001){ref-type="supplementary-material"}**), HHV-7 (**[S1G Fig](#pone.0184699.s001){ref-type="supplementary-material"}**), and HHV-8 (**[S1H Fig](#pone.0184699.s001){ref-type="supplementary-material"}**). The rate of positive EBV infection alone was significantly higher in the IS therapy group than in the non-IS therapy group (P = 0.025).

Mucosal HHV PCR positivity rate in untreated HIV-infected individuals with low CD4 and treated HIV-infected individuals {#sec017}
-----------------------------------------------------------------------------------------------------------------------

There were 8 (36.4%) untreated HIV-infected individuals with low CD4 T (\< 100 cells/μL). **[S2 Fig](#pone.0184699.s002){ref-type="supplementary-material"}** shows the positivity rate of the eight HHVs in colonic mucosa and a comparison between the untreated HIV-infected individuals with low CD4 T and the treated HIV-infected individuals for HSV-1 (**[S2A Fig](#pone.0184699.s002){ref-type="supplementary-material"}**), HSV-2 (**[S2B Fig](#pone.0184699.s002){ref-type="supplementary-material"}**), VZV (**[S2C Fig](#pone.0184699.s002){ref-type="supplementary-material"}**), EBV (**[S2D Fig](#pone.0184699.s002){ref-type="supplementary-material"}**), CMV (**[S2E Fig](#pone.0184699.s002){ref-type="supplementary-material"}**), HHV-6 (**[S2F Fig](#pone.0184699.s002){ref-type="supplementary-material"}**), HHV-7 (**[S2G Fig](#pone.0184699.s002){ref-type="supplementary-material"}**), and HHV-8 (**[S2H Fig](#pone.0184699.s002){ref-type="supplementary-material"}**). We found that the HHV-7 infection rate was significantly higher in the untreated HIV group with low CD4 than in the treated HIV group.

Discussion {#sec018}
==========

We used mucosal PCR assay to examine the detection rates of eight HHVs in colonic mucosa from colonoscopic biopsy specimens of ulcerated lesions in IC, IBD, and HIV-infected individuals. EBV, CMV, HHV-6, and HHV-7, but not HSV-1, HSV-2, VZV, and HHV-8, were identified in the colonic mucosa of IBD individuals. Also, the positivity rates of EBV and CMV, but not of the other HHVs, increased significantly in the order of the IC, IBD, and HIV groups. We confirmed this finding by quantitative PCR. There was no significant difference in positivity rate of the eight HHVs between UC and CD individuals.

The ECCO has reported various cases of HHV infection in IBD individuals, but no studies have comprehensively investigated the rates of mucosal infections in IBD.\[[@pone.0184699.ref008]\] Generally, after initial asymptomatic infection, many types of HHVs become latent in certain organs. HSV-1, HSV-2, and VZV reportedly remain in the ganglion, CMV in the glandular system, and EBV, HHV-6, HHV-7, and HHV-8 in the lymphatic tissues,\[[@pone.0184699.ref016],[@pone.0184699.ref017]\] and they are reactivated as the host immune system weakens. Upon reactivation, HSV-1, HSV-2, and VZV are transported from the latently infected ganglia to the skin where the viruses will be shed via skin lesions.\[[@pone.0184699.ref016]\] This may explain why these viruses have not been detected in the colonic mucosa. Consistent with our findings, Wakefield et al. reported negative PCR results for HSV-1 and VZV in the colonic mucosa of all IBD individuals tested.\[[@pone.0184699.ref018]\] Conversely, in our study, colonic HHV-8 infection was confirmed in HIV-infected individuals alone. Lavagna et al. performed PCR to compare HHV infection status in colonic mucosa between IBD individuals and those who had undergone colonic cancer surgery (the control group) and found that HHV-8 was negative in all individuals in both groups.\[[@pone.0184699.ref019]\] This was also consistent with our findings, possibly due to the high risk of HHV-8 transmission through anal intercourse and saliva in men.\[[@pone.0184699.ref020]\] This study found CMV, EBV, HHV-6, and HHV-7 infection in the colonic mucosa of IBD individuals, probably due to latent infection of tissues (e.g. glandular and lymphatic tissues) in the intestinal tract.\[[@pone.0184699.ref016],[@pone.0184699.ref017]\] CMV mainly infects monocytes, which differentiate into macrophages following stimulation by inflammatory cytokines.\[[@pone.0184699.ref017]\] During the differentiation and stimulation process, CMV can be reactivated and proceed to infect epithelial, vascular endothelial, and interstitial cells.\[[@pone.0184699.ref016]\] EBV mainly infects B-lymphocytes and can also be reactivated by various stimuli; reactivated EBV infects various cells including T lymphocytes, natural killer cells, and epithelial cells. It has been reported that HHV-6 infects monocytes and promyelocytes and that HHV-7 infects CD4+ T lymphocytes mainly; they tend to have a broader spectrum of infection following reactivation in response to stimuli. \[[@pone.0184699.ref016]\]

Previously, it was reported that positivity rates in IBD individuals for mucosal infection by EBV and CMV were 48.3--62.5%\[[@pone.0184699.ref021],[@pone.0184699.ref022]\] and 10--36%,\[[@pone.0184699.ref023],[@pone.0184699.ref024]\] respectively, which are consistent with our findings of 49.4% and 27.0%, respectively. Nahar et al. tested stool samples by PCR to compare positivity rates for HHV-1 to HHV-6 between an IC group and an immunocompromised group (including HIV infection) and found significantly higher positivity rates for both viruses in the latter group than in the former group (P \< 0.05).\[[@pone.0184699.ref007]\] Based on these previous findings, it is highly likely that mucosal infection rates for EBV and CMV are higher in IBD and HIV-infected individuals than in IC individuals. There is no consensus on the differences in CMV infection rates between UC and CD individuals. McCurdy et al. performed histopathology of colonic mucosa and found that CMV infection rates were significantly higher in UC individuals (P = 0.003).\[[@pone.0184699.ref025]\] Nakase et al. showed differences in colonic immunity between the two groups; CD4+ T cells produce IFN-α that inhibits CMV reactivation in CD but not in UC individuals, resulting in suppressed reactivation of CMV in CD individuals.\[[@pone.0184699.ref026]\] Conversely, Ormeci et al. tested CMV infection by mucosal PCR but found no significant difference in infection rate between UC individuals (12%) and CD individuals (19%).\[[@pone.0184699.ref027]\] In the present study, CMV infection rates were slightly higher in the UC individuals, albeit no significance so, partly due to the limited number of cases tested. A future study including more cases is needed. In agreement with our study, a previous study showed no significant differences in colonic infection rates by HSV-1, VZV, EBV, and HHV-6 between UC and CD individuals.\[[@pone.0184699.ref018]\]

This study has several limitations. First, it is a single-center study. Second, all participants in the HIV group were men, so there was selection bias. Third, we had no information on the precise location or size of the ulcers and thus could not assess the association between ulcer location and HHV detection. Fourth, there was a low prevalence of HSV-1/2, VZV, and HHV-8 in the relatively small number of IBD individuals and IBD individuals showed heterogeneity in our study. Further studies with more IBD individuals are needed.

In conclusion, among the eight HHVs investigated, EBV, CMV, HHV-6, and HHV-7, but not HSV-1, HSV-2, VZV, or HHV-8, were identified in the colonic mucosa of IBD individuals. EBV and CMV in colonic mucosa was correlated with host immune status in increasing order of IC, IBD, and HIV-infected individuals.

Supporting information {#sec019}
======================

###### Mucosal HHV PCR positivity rate in the immunosuppressive (IS) and the non-IS therapy group (n = 41).

**Note**: Bars represent standard error. **Abbreviations**: CMV, cytomegalovirus; EBV, Epstein--Barr virus; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV-1/2, herpes simplex virus-1/2; NA, not applicable; VZV, varicella zoster virus.

(TIF)

###### 

Click here for additional data file.

###### Mucosal HHV PCR positivity rate in the untreated HIV group with low CD4 and the treated HIV group (n = 22).

**Note**: Bars represent standard error. **Abbreviations**: CMV, cytomegalovirus; EBV, Epstein--Barr virus; HHV, human herpesvirus; HIV, human immunodeficiency virus; HSV-1/2, herpes simplex virus-1/2; NA, not applicable; VZV, varicella zoster virus.

(TIF)

###### 

Click here for additional data file.
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